Biomind LabsBMNDF 30 Market Cap is $8.19 Mil as of Jun. 29, 2026. GuruFocus rates BMNDF with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,428 Biotechnology companies, Biomind Labs ranks worse than 86.34% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biomind Labs's share price for the quarter that ended in Mar. 2026 was $0.011. Biomind Labs's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 77.57 Mil. Therefore, Biomind Labs's market cap for the quarter that ended in Mar. 2026 was $0.85 Mil.
Biomind Labs's quarterly market cap
increased
from Sep. 2025 ($1.23 Mil) to Dec. 2025 ($8.84 Mil) but then
declined
from Dec. 2025 ($8.84 Mil) to Mar. 2026 ($0.85 Mil).
Biomind Labs's annual market cap
increased
from Dec. 2023 ($7.48 Mil) to Dec. 2024 ($23.86 Mil) but then
declined
from Dec. 2024 ($23.86 Mil) to Dec. 2025 ($8.84 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biomind Labs's Enterprise Value for Today is $8.97 Mil.
Biomind Labs (OTCPK:BMNDF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biomind Labs Market Cap Related Terms
Biomind Labs Market Cap Historical Data
* Premium members only.
The historical data trend for Biomind Labs's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Biomind Labs's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomind Labs Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biomind Labs's Market Cap distribution charts can be found below:
* The bar in red indicates where Biomind Labs's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biomind Labs's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomind Labs (BMNDF) has a Market Cap of $8.19 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biomind Labs and its competitors. According to the industry distribution chart, Biomind Labs ranks #1233 out of 1428 companies in the Biotechnology industry, placing it in the top 86.3%.
Is Biomind Labs' Market Cap too high?
Biomind Labs' current Market Cap is $8.19 Mil. The Biotechnology industry median Market Cap is 114.03. Biomind Labs' value of $8.19 Mil is 92.8% below this industry median. Based on the distribution chart, Biomind Labs ranks #1233 out of 1428 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biomind Labs has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Biomind Labs' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biomind Labs ranks #1233 out of 1428 companies for Market Cap. This places Biomind Labs in the lower half of its industry. The industry median Market Cap is 114.03. Biomind Labs' value of $8.19 Mil is 92.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomind Labs's current Market Cap of $8.19 Mil is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biomind Labs and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomind Labs's current Market Cap is $8.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomind Labs stock overvalued right now?
Biomind Labs (BMNDF) has a current Market Cap of $8.19 Mil. The current Market Cap is $8.19 Mil and 92.8% below the Biotechnology industry median of 114.03. Biomind Labs' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Biomind Labs (BMNDF), the current Market Cap is $8.19 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomind Labs Inc is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The firm is developing pharmaceutical solutions and combined formulations of the main natural psychedelic molecules with the objective of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.
30GF Score
Get the complete analysis for BMNDF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMNDF has been successfully added to your 
